Other Clinical Trial - Analytical Specificity of Bladder EpiCheck Test in

Updated 04/26/2024

Status Completed

Clinical Trial Summary

This is a prospective study to establish the analytical specificity of Bladder EpiCheck test in urine samples from healthy population and urology patients without prior history or evidence of bladder cancer.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Non Muscle Invasive Bladder Cancer
Non-Muscle Invasive Bladder Urothelial Carcinoma
Urinary Bladder Neoplasms

Clinical Trial Details

NCT number	NCT06020807
Study type	Observational
Source	Nucleix Ltd.
Contact
Status	Completed
Phase
Start date	September 5, 2019
Completion date	January 8, 2020

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT06167356` - Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.
	Withdrawn	`NCT01799499` - A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC)	N/A
	Completed	`NCT02343614` - Celecoxib for the Treatment of Non-muscle Invasive Bladder Cancer	Phase 2
	Recruiting	`NCT05945108` - Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER
	Recruiting	`NCT06287541` - The Necessity of a Second Transurethral Resection in High-risk Non-muscle-invasive Bladder Cancer Patients With Negative Urine Biomarker After Initial Transurethral Resection	N/A
	Recruiting	`NCT06181266` - A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer	Phase 1
	Terminated	`NCT02982395` - Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC	Phase 3
	Completed	`NCT06205277` - Predictors of Residual Tumor at Second Transurethral Resection for pT1 Non-muscle Invasive Bladder Cancer
	Completed	`NCT01731652` - Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer	Phase 2
	Recruiting	`NCT03421236` - Intravesical Ty21a for the Treatment of Patients With Non-muscle-invasive Bladder Cancer (NMIBC)	Phase 1
	Active, not recruiting	`NCT04387461` - Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin	Phase 2
	Recruiting	`NCT06111235` - A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT	Phase 3
	Recruiting	`NCT02895620` - Effect on Xpert® Bladder Test of Urines Inflammatory Milieu Induced by BCG Treatment of Patients With NMIBC	N/A
	Completed	`NCT01004211` - Prospective Randomized Comparison of Transurethral Resection by Mean of White Light and Narrow Band Imaging	N/A
	Active, not recruiting	`NCT05981131` - Follow up of Intravesical N-803 Plus BCG in BCG-Naive Non-Muscle Invasive Bladder Cancer (NMIBC)